IGC compared with NEUP: revenue, margins and what each company keeps, and the suppliers and customers both name

IGCIGC Pharma, Inc.

Mkt capRevenueRevenue

NEUPNeuphoria Therapeutics Inc.

Mkt capRevenueRevenue

Compare

IGCIGC Pharma, Inc.

NEUPNeuphoria Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

IGC, solidNEUP, dashed

Supply-chain overlap

Revenue flow

IGC: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only IGC 0

None

Shared 0

No disclosed counterparties: IGC.

Only NEUP 6

MRKMerckcustomer

—Danforth Advisorsunlistedsupplier

—Wolf & Company, P.Cunlistedsupplier

—WG Partners LLPunlistedsupplier

2 more · NEUP chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

IGCIGC Pharma, Inc.

0.20▼−0.10%· post 0.18

Mkt cap$18.6MRevenue$265,000Q2 FY26Revenue$1MFY25

NEUPNeuphoria Therapeutics Inc.

3.07▲+0.33%· post 3.07

ClosedOct 30 '26

Mkt cap$16.5MRevenue$15MQ3 FY25Revenue—

Compare

ClosedOct 30 '26

IGCIGC Pharma, Inc.

NEUPNeuphoria Therapeutics Inc.

0.20▼−0.10%post 0.18

Price

3.07▲+0.33%post 3.07

$18.6M

Mkt cap

$16.5M

Q2 FY26$265,000

Revenue

$15MQ3 FY25

FY25$1M

Revenue

—

IGC0.20▼−0.10%vsNEUP3.07▲+0.33%ClosedOct 30 '26